Mometasone Furoate Nasal spray
DrugOne dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
Other names: Nasonex, SCH 032088
NCT Number: NCT00817050
This was a one-day single dose trial conducted to compare patient's preference for Nasonex® (mometasone) versus Flonase® nasal spray. Each patient was randomized to take one dose (2 sprays in each nostril) of Nasonex or Flonase. Thirty minutes later, each patient was to take one dose of the opposite medication. Questionnaires were given to each patient after each drug dose to evaluate patient product preference.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 4
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
Other names: Nasonex, SCH 032088
One dose (2 sprays in each nostril) of fluticasone nasal spray
Other names: Flonase®
Time frame: On the study day, after dose of each product
Time frame: On the study day, after dose of each product
Time frame: On the study day, after dose of each product
Time frame: On the study day, after dose of each product
Time frame: On the study day, after dose of each product
Time frame: On the study day, after dose of each product
Looking for future studies?
Notify MeOrganon and Co
Industry
A Preference Evaluation of Nasonex® Nasal Spray (Unscented) vs. Flonase® Nasal Spray (Scented) in Subjects With Symptomatic Allergic Rhinitis (AR) - Single-Dose Cross-over
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05214911
Allergic Rhinitis, Hypersensitivity
São Paulo, Brazil
View Trial DetailsNCT04152746
Adenoid Hypertrophy, Allergic Rhinitis
Istanbul, Fatih, Turkey (Türkiye)
View Trial DetailsNCT07778537
Allergic Rhinitis, Hypersensitivity
Beijing, Beijing Municipality, China
View Trial DetailsNCT07453615
Allergic Rhinitis, Anxiety
Antalya, Turkey (Türkiye)
View Trial Details